trisalicylate choline
Choline magnesium trisalicylate is a non-acetylated salicylate used widely as a nonsteroidal anti-inflammatory drug. Choline magnesium trisalicylate inhibits inflammation-related prostaglandin synthesis. Choline magnesium trisalicylate is used to relieve the pain, tenderness, inflammation (swelling), and stiffness caused by arthritis and painful shoulder. It is also used to relieve pain and lower fever. Salicylate intoxication, known as salicylism, may occur with large doses or extended therapy. Common symptoms of salicylism include headache, dizziness, tinnitus, hearing impairment, confusion, drowsiness, sweating, vomiting, diarrhea, and hyperventilation. A more severe degree of salicylate intoxication can lead to CNS disturbances, alteration in electrolyte balance, respiratory and metabolic acidosis, hyperthermia, and dehydration. — NCATS
Clinical trial activity
3 trials · 3 clinical orgs · 0 marketing orgs
Earliest trial started Mar 1, 2003 (NCT00156299)
Timeline
Indications
Mechanism of action
- MethotrexateBLOCKER
Methotrexate blocker
Chemistry & pharmacology
SMILES
[Mg++].C[N+](C)(C)CCO.OC1=C(C=CC=C1)C([O-])=O.OC2=C(C=CC=C2)C([O-])=O.OC3=C(C=CC=C3)C([O-])=O- Mol. weight
- 539.8142 g/mol
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- NCATSDJJ95FJP1H ↗
- ChEMBLCHEMBL4297727 ↗
Also known as
- ((1,2-ethanediylbis(carbamodithioato))(2-))manganese, mixt. with ((1,2-ethanediylbis(carbamodithioato))(2-))zinc &2(or 4)-isooctyl-4,6(or 2,6)-dinitrophenyl 2-buten oate
- choline magnesium trisalicylate
- choline magnesium trisalicylate
- choline magnesium trisalicylate
- choline magnesium trisalicylate
- choline magnesium trisalicylate
- tegunor
- tricosal
- trilisate
- trilisate
- trisalicylate choline
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01009931 | Phase 2 | Mar 1, 2011 | Biosuccess Biotech Co., Ltd., National Cancer Institute (NCI), Rutgers University |
| NCT02144675 | Phase 2 | Jan 1, 2009 | National Cancer Institute (NCI), Rutgers University |
| NCT00156299 | Phase 1 | Mar 1, 2003 | National Cancer Institute (NCI), Rutgers University |
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | Government | 3 | 0 | 2 | 2003 |
| Rutgers University | Academic/Hospital | 3 | 3 | 2 | 2003 |
| Biosuccess Biotech Co., Ltd. | For profit | 1 | 0 | 1 | 2011 |